IR Insights: Recapping Moderna’s Science Day
Yesterday, Moderna announced research and early development updates at our Science Day event.
Members of our executive team sat down to provide more insight into our strategy that balances near-term growth with long-term innovation. Watch our latest IR Insights video below to hear from Stéphane Bancel, CEO, David Berman, Chief Development Officer, and Rose Loughlin, Executive Vice President of Research.
Stay tuned for more updates and follow us on LinkedIn and X to learn more about Moderna and how we’re changing the future of medicine.
Forward-Looking Statements
This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential of Moderna’s mRNA platform and promise as a multi-modality biotechnology company; anticipated 2026 sales growth and future growth; Moderna’s potential three commercial franchises; Moderna’s path to cash breakeven by 2028; potential product approvals; anticipated infectious disease launches in 2027 and 2028; the PDUFA goal date for mRNA-1010; anticipated geographic expansion; potential pivotal data readouts in 2026 for intismeran and propionic acidemia, which could support possible launches; Moderna’s future growth drivers; Moderna’s emerging oncology programs; Moderna’s T-cell engager modality and the encouraging early clinical signal with mRNA-2808; Moderna’s in vivo CAR-T modality and the potential in autoimmune diseases, as well as oncology; Moderna’s ongoing and planned clinical studies; expected market sizes for Moderna’s products and future products; and anticipated progress and milestones for Moderna’s programs, including anticipated data readouts and timing. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this post.